SC
TBRA

Sophrosyne Capital’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

Sophrosyne Capital’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,744
Closed -$310K – 89
2014
Q1 		$310K Buy
+2,744
New +$193K 0.27% 55

Other funds holding TBRA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIA
Biondo Investment Advisors Milford, Pennsylvania $780M AUM 21.03% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $2.46B AUM 57.16% 1-Year Est. Return

Sophrosyne Capital's TBRA Position: Q2 2014 in Review

Sophrosyne Capital sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q2 2014, closing a stake of 2,744 shares — an estimated $310K sold.

Sophrosyne Capital first reported a position in TBRA in Q1 2014 and held it in 1 quarter. The position peaked at $310K in Q1 2014. 49 funds tracked by Wall St. Rank hold TBRA as of Q2 2014.

  • Sophrosyne Capital reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 2,744 Tobira Therapeutics, Inc. Common Stock shares in Q2 2014, an estimated $310K.
  • Sophrosyne Capital first reported a position in Tobira Therapeutics, Inc. Common Stock in Q1 2014 and held it in 1 quarter.
  • Sophrosyne Capital's Tobira Therapeutics, Inc. Common Stock position peaked at $310K in Q1 2014.
  • 49 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q2 2014.

Based on Sophrosyne Capital's 13F filing for Q2 2014, filed 14 Aug 2014.